Moderate hypothermia for postarrest with nonshockable rhythm: HYPERION

  • Lascarrou JB & al.
  • N Engl J Med
  • 2 Oct 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with cardiac arrest arising from nonshockable rhythms (asystole or pulseless electrical activity) might benefit from moderate therapeutic hypothermia (MTH).
  • This trial’s main result was marginally significant.

Why this matters

  • Hypothermia is recommended for patients in persistent coma after resuscitated out-of-hospital cardiac arrest. 
  • Several retrospective case series examining it for the subgroup with nonshockable rhythm have had variable conclusions.
  • Nonshockable rhythms are the most common type in patients with cardiac arrest and carry a poor prognosis.

Key results

  • MTH vs normothermia:
    • 90-day survival with favorable neurologic outcome:
      • 10.2% (29/284) vs 5.7% (17/297);
      • Difference, 4.5% (95% CI, 0.1-8.9; P=.04).
    • 90-day mortality:
      • 81.3% vs 83.2%;
      • Difference, −1.9% (95% CI, −8.0 to 4.4).
    • Similar rates of mechanical ventilation duration, ICU length of stay.
    • Similar adverse event rates. 

Study design

  • Open-label, multicentre, randomised controlled HYPERION trial (n=581).
  • Participants were adults experiencing coma after resuscitation from cardiac arrest because of nonshockable rhythm from any cause.
  • They were randomly assigned to undergo MTH (33ºC in the first 24 hours) vs normothermia.
  • Outcomes: 90-day survival with favorable neurologic outcome.
  • Funding: French Ministry of Health; Center Hospitalier Départemental Vendée; Laerdal Foundation.

Limitations

  • Outcome change in 1 patient would render primary outcome difference insignificant.
  • Some hyperthermia occurred in control group.